Alector has introduced atozinemab, a groundbreaking investigational human monoclonal antibody crafted to obstruct sortilin, thereby boosting progranulin (PGRN) levels, offering promise in treating frontotemporal dementia with a progranulin gene mutation (FTD-GRN).
Meanwhile, Latozinemab (AL001) represents another investigational human monoclonal antibody tailored to regulate progranulin (PGRN), a pivotal regulator of brain immune activity associated with various neurodegenerative disorders such as frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. Latozinemab seeks to enhance PGRN levels by inhibiting sortilin, a receptor involved in PGRN degradation.
Frontotemporal dementia (FTD) is a rare yet significant neurodegenerative condition, often leading to early onset dementia. Its impact is felt by an estimated 50,000 to 60,000 individuals in the United States and approximately 110,000 in the European Union, with potentially higher prevalence rates in Asia and Latin America.
Latozinemab emerges as the frontrunner among progranulin-elevating candidates in FTD-GRN development, earning the prestigious designation as the first investigational medicine to receive breakthrough therapy recognition for treating Progranulin Gene Mutation (FTD-GRN).
Alector announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to latozinemab, an investigational human monoclonal antibody designed to block sortilin, thereby elevating progranulin (PGRN) levels.
